42.02% -0.0366

Bio Path Holdings Inc (BPTH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Bio Path Holdings Inc Stock (BPTH) Company Profile

Bio Path Holdings Inc

Healthcare (1110)

Biotechnology (621)

Prossima data di guadagno

Ultimi documenti SEC

BPTH's Discussions on Twitter

Compare BPTH vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BPTH Bio Path Holdings Inc	0.05	0	0	-8.67M	-1.60M	-1.0985
VRTX Vertex Pharmaceuticals Inc	438.39	109.09B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	709.98	74.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.81	48.64B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.41	39.39B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	314.32	32.38B	5.36B	287.73M	924.18M	2.5229

Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-03-11	Iniziato	ROTH Capital	Buy
2017-11-13	Reiterato	H.C. Wainwright	Buy
2016-08-10	Reiterato	Maxim Group	Buy
2016-04-18	Iniziato	Rodman & Renshaw	Buy
2014-06-02	Ripresa	Maxim Group	Buy
2014-05-09	Iniziato	Maxim Group	Buy

Mostra tutto

Bio Path Holdings Inc Borsa (BPTH) Ultime notizie

Bio Path Holdings Inc Azioni (BPTH) Dati Finanziari

Bio Path Holdings Inc (BPTH)

Bio Path Holdings Inc Stock (BPTH) Company Profile

Compare BPTH vs VRTX, REGN, ARGX, ALNY, ONC

Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades

Bio Path Holdings Inc Borsa (BPTH) Ultime notizie

Standex International Corporation 2026 Q1 Financial Results and SEC Filing Overview - Minichart

Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path - Barchart.com

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues - Yahoo Finance

[1-K] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan

Leading Companies Consolidating Their Presence in the Antisense and RNAi Therapeutics Market - openPR.com

MSN Money - MSN

RNA Therapies Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com

Marginal Zone Lymphoma Clinical Trial Pipeline Expands as 50+ - openPR.com

Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ - openPR.com

Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path Holdin - Barchart.com

Layoff Tracker: Replimune lays off over 200 in Massachusetts - BioSpace

5E Advanced Materials, Inc. Files Form 8-K with Nasdaq Listing Details and Emerging Growth Company Status - Minichart

In-Depth Examination of Segments, Industry Trends, and Key - openPR.com

Microbot Medical Inc. (MBOT) stock price, news, quote and history - Yahoo Finance Australia

Stock List: Research Stocks from Around the World - GuruFocus

USA Stocks: Research Stocks from USA Stock Market - GuruFocus

Analyzing Bio-Path (BPTH) and Its Rivals - defenseworld.net

IXICO Taps Tech Bio Path with Strategic Medidata Deal - kalkinemedia.com

Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener

[1-A] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan

Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Shows Potential with Active Contributions from 70+ Key Companies | DelveInsight - Barchart.com

Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock - Minichart

Bio-Path Holdings approves Wyoming move and creates new preferred stock class - Investing.com Australia

[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event - Stock Titan

Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) - Defense World

SEC Filings for Mar 19, 202610-K, 10-Q, 8-K Forms - Stock Titan

Gossamer Bio 2025 Annual Report: Seralutinib PAH Clinical Development, FDA Path, and Regulatory Strategy Insights - Minichart

Vuzix Reports 2025 Financial Results, Secures $20M Quanta Investment, and Advances Waveguide & OEM Smart Glasses Growth - Minichart

T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com

T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ - openPR.com

Is Bio Path Holdings Inc. (IBP0) stock a defensive play amid uncertaintyQuarterly Trade Review & Long Hold Capital Preservation Plans - Naître et grandir

[1-Z] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan

Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split By Investing.com - Investing.com South Africa

Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split - Investing.com Australia

Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan

BPTHBio-Path Hldgs Inc Latest Stock News & Market Updates - Stock Titan

Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World

Can Bio Path Holdings Inc. (IBP0) stock surprise markets with earningsRate Cut & AI Optimized Trade Strategies - mfd.ru

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - Yahoo Finance

Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com

Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working In The Domain Delveinsight - Mena FN

Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com

Acute Myeloid Leukemia Market Forecast to 2034: 7MM - openPR.com

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer - Yahoo Finance

Antisense Oligonucleotide Therapeutics Clinical Trial - openPR.com

Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com

Bio-Path Holdings Q3 2025: Loss of $976K, Shares at $0.07News and Statistics - IndexBox

Bio-Path: Third Quarter Financial Highlights - Bitget

Bio-Path: Q3 Earnings Snapshot - Barchart.com

BPTH: Operational pause, depleted cash, and debt defaults highlight urgent need for new funding - TradingView

BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView

Bio Path Holdings Inc Azioni (BPTH) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a BPTH